Company Profile

Adeptrix Corporation
Profile last edited on: 3/24/2021      CAGE: 66QV9      UEI: UD9UKVEQNV49

Business Identifier: Mass spectrometry-based, high-content and high-throughput microarray platform for screening changes
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 Cummings Center 438Q
Beverly, MA 01915
   (617) 302-6669
Location: Single
Congr. District: 06
County: Essex

Public Profile

Adeptrix Corporation s structured around development and manufacture of analytical reagents and assays based on the company’s proprietary platform technology designated Bead Assisted Mass Spectrometry (BAMS). BAMS™ is an innovative and powerful analytical platform enabling immunoassays to be measured by MALDI mass spectrometry for rapid, precise and sensitive target analyte detection. The BAMS platform technology is both (1) multiplexed -- capable of measuring multiple target analytes in a single assay -- and (2) high-throughput: capable of measuring hundreds to thousands of assays per day. These two factors make the system of va;lue and utility in a wide range of bio-analytical applications in drug development, basic research and clinical diagnostics.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Vladislav Bergo -- Co-Founder, CEO, Chief Scientific Officer

  Tamilselvan Anthonymuthu

  Sergey Mamaev -- Senior Research Scientist

  Norman Priebatsch -- Co-founder

  Jeffrey C Silva -- Director of Product Development

  Lykourgos Tzioumas -- Lab Technician

  Camilla Worsfold -- Research Scientist

Company News

There are no news available.